Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BioRestorative Therapies, Inc.
Report date October 06, 2025 · Filed October 20, 2025
Section 16 reporting ended · disclosed 2025-10-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Comon StockSEC Table I · non-derivative | Direct | 171,384 |
Reported balance
After 2025-10-06 transaction · row 1
1 source rowRow 1 · 2025-10-06 · Grant · Acquired 11,719 · Balance 171,384 |
| WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2030-10-08 | Direct | 11,719 |
Reported balance
After 2025-10-06 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-10-06 · Grant · Acquired 11,719 · Balance 11,719 |
| Common StockSEC Table I · non-derivative | IndirectIRA | 12,136 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 12,136 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3,000.00 · Expires 2026-06-10 | Direct | 15 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 15 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3,000.00 · Expires 2027-07-12 | Direct | 20 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance 20 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3,000.00 · Expires 2028-10-29 | Direct | 25 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 25 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-03-18 | Direct | 293,479 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 293,479 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-11-04 | Direct | 42,059 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · Balance 42,059 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2033-02-17 | Direct | 106,762 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · Balance 106,762 F2: The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2034-02-13 | Direct | 394,737 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · Balance 394,737 F3: The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.46 · Expires 2035-02-14 | Direct | 768,979 |
Reported balance
Holding disclosure · report date 2025-10-06 · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · Balance 768,979 F4: The option vests and becomes exercisable to the extent of 384,490 shares on February 14, 2025 and 384,489 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is currently exercisable.
F2: The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 and 53,381 shares in eight nearly equal quarterly installments beginning February 17, 2024 and continuing every three months thereafter until fully vested.
F3: The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested.
F4: The option vests and becomes exercisable to the extent of 384,490 shares on February 14, 2025 and 384,489 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2025 Filed Oct 20, 2025 12:18 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantWarrant · Derivative | 11,719 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001021771-25-000141 · form4.xml · derivative · entry 11 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,719 Underlying: Common Stock · 11,719 shares Expires 2030-10-08 Read SEC document |
| October 06, 2025 Filed Oct 20, 2025 12:18 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantComon Stock | 11,719 | $1.60 | $18,750.40 |
DisclosureSEC source: 0001021771-25-000141 · form4.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 171,384 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:25 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 768,979 | $0.00 Strike: $2.46 | $0.00 |
DisclosureSEC source: 0001021771-25-000038 · form4.xml · derivative · entry 11 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 768,979 Underlying: Common Stock · 768,979 shares Expires 2035-02-14 F4 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 384,490 shares on February 14, 2025 and 384,489 shares in eight nearly equal quarterly installments beginning February 14, 2026 and continuing every three months thereafter until fully vested. Read SEC document |
| April 09, 2024 Filed Apr 10, 2024 21:16 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 6,600 | $1.25 | $8,250.00 |
DisclosureSEC source: 0001021771-24-000091 · form4.xml · nonDerivative · entry 3 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,759 Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:16 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 1,232 | $1.17 | $1,441.44 |
DisclosureSEC source: 0001021771-24-000091 · form4.xml · nonDerivative · entry 2 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,159 Read SEC document |
| April 08, 2024 Filed Apr 10, 2024 21:16 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 476 | $1.13 | $537.88 |
DisclosureSEC source: 0001021771-24-000091 · form4.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,927 Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:38 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Tax withholdingCommon Stock | 17,193 | $1.39 | $23,898.27 |
DisclosureSEC source: 0001021771-24-000079 · form4.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,451 F1 · kind: Shares were withheld from vested stock grant to pay the associated withholding taxes. Read SEC document |
| February 13, 2024 Filed Feb 15, 2024 21:13 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 394,737 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001021771-24-000046 · form4.xml · derivative · entry 13 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 394,737 Underlying: Common Stock · 394,737 shares Expires 2034-02-13 F5 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 197,369 shares on February 13, 2024 and 197,368 shares in eight nearly equal quarterly installments beginning February 13, 2025 and continuing every three months thereafter until fully vested. Read SEC document |
| August 31, 2023 Filed Aug 31, 2023 17:54 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 4,954 | $2.22 | $10,997.88 |
DisclosureSEC source: 0001021771-23-000086 · form4.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,644 F1 · balance_after: Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 11:00 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 747 | $3.56 | $2,659.32 |
DisclosureSEC source: 0001021771-23-000034 · form4.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 159,690 F1 · balance_after: Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 20:49 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Tax withholdingCommon Stock | 6,729 | $2.92 | $19,648.68 |
DisclosureSEC source: 0001021771-23-000028 · form4.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development · 10% owner 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,943 F1 · kind: Shares were withheld from vested stock grant to pay the associated withholding taxes. F2 · balance_after: Includes 48,912 shares received pursuant to an unvested restricted stock unit grant. Such shares vest on March 18, 2024. Read SEC document |
| February 18, 2023 Filed Feb 28, 2023 12:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Tax withholdingCommon Stock | 374 | $2.99 | $1,118.26 |
DisclosureSEC source: 0001567619-23-003891 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,672 F1 · kind: Shares were withheld from vested stock grant to pay the associated withholding taxes. F2 · balance_after: Includes 98,862 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| February 17, 2023 Filed Feb 17, 2023 22:29 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 106,762 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001567619-23-003326 · doc1.xml · derivative · entry 13 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,762 Underlying: Common Stock · 106,762 shares Expires 2033-02-17 F5 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 53,381 shares on February 17, 2023 with the remaining 53,381 shares vesting in eight nearly-equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested. Read SEC document |
| November 21, 2022 Filed Nov 21, 2022 22:14 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 943 | $2.62 | $2,467.08 |
DisclosureSEC source: 0001567619-22-020707 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,046 F1 · balance_after: Includes 101,972 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 1,037 shares on December 18, 2022 and February 18, 2023, 1,036 shares on January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 42,059 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001567619-22-019198 · doc1.xml · derivative · entry 15 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,059 Underlying: Common Stock · 42,059 shares Expires 2031-11-04 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F4 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 42,059 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-22-019198 · doc1.xml · derivative · entry 14 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,059 shares Expires 2031-11-04 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F4 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 293,479 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001567619-22-019198 · doc1.xml · derivative · entry 13 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,479 Underlying: Common Stock · 293,479 shares Expires 2031-03-18 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F3 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 20:27 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 293,479 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-22-019198 · doc1.xml · derivative · entry 12 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 293,479 shares Expires 2031-03-18 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F3 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested. Read SEC document |
| October 12, 2022 Filed Oct 12, 2022 18:01 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 725 | $3.39 | $2,456.59 |
DisclosureSEC source: 0001567619-22-018437 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,103 F1 · balance_after: Includes 104,045 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on each of October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on each of November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| October 11, 2022 Filed Oct 12, 2022 12:54 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 806 | $3.69 | $2,973.01 |
DisclosureSEC source: 0001567619-22-018424 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,378 F1 · price: This transaction was executed in multiple trades at prices ranging from $3.68 to $3.70 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 104,045 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on each of October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on each of November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| August 29, 2022 Filed Sep 9, 2022 22:17 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 307 | $3.32 | $1,018.93 |
DisclosureSEC source: 0001567619-22-017246 · doc1.xml · nonDerivative · entry 4 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 12,136 F4 · price: This transaction was executed in multiple trades at prices ranging from $3.28 to $3.35 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| August 29, 2022 Filed Sep 9, 2022 22:17 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,816 | $3.21 | $9,047.81 |
DisclosureSEC source: 0001567619-22-017246 · doc1.xml · nonDerivative · entry 3 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,572 F3 · price: This transaction was executed in multiple trades at prices ranging from $3.21 to $3.2159 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 105,081 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,036 shares on each of September 18, 2022, November 18, 2022 and January 18, 2023, 1,037 shares on each of October 18, 2022, December 18, 2022 and February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| August 26, 2022 Filed Sep 9, 2022 22:17 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,600 | $3.35 | $8,710.00 |
DisclosureSEC source: 0001567619-22-017246 · doc1.xml · nonDerivative · entry 2 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,756 F2 · balance_after: Includes 105,081 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,036 shares on each of September 18, 2022, November 18, 2022 and January 18, 2023, 1,037 shares on each of October 18, 2022, December 18, 2022 and February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| August 26, 2022 Filed Sep 9, 2022 22:17 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | SaleCommon Stock | 3,958 | $3.39 | $13,409.70 |
DisclosureSEC source: 0001567619-22-017246 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,156 F1 · price: Represents transaction inadvertently effected by the reporting person. This transaction was executed in multiple trades at prices ranging from $3.33 to $3.45 per share. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 105,081 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,036 shares on each of September 18, 2022, November 18, 2022 and January 18, 2023, 1,037 shares on each of October 18, 2022, December 18, 2022 and February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| June 14, 2022 Filed Jun 15, 2022 18:55 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantCommon Stock | 263 | $3.78 | $993.46 |
DisclosureSEC source: 0001567619-22-012893 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,114 F1 · balance_after: Includes 108,191 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on June 18, 2022, August 18, 2022, October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on July 18, 2022, September 18, 2022, November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 13:37 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantCommon Stock | 565 | $4.65 | $2,626.85 |
DisclosureSEC source: 0001567619-22-012496 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,851 F1 · price: This transaction was executed in multiple trades at prices ranging from $4.635 to $4.69 per share. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide, upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Includes 108,191 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares on June 18, 2022, August 18, 2022, October 18, 2022, December 18, 2022 and February 18, 2023, 1,036 shares on July 18, 2022, September 18, 2022, November 18, 2022 and January 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| March 18, 2022 Filed Mar 22, 2022 21:11 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantCommon Stock | 12,438 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-22-007349 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,286 F1 · price: Shares received pursuant to a restricted stock unit grant. Vests in twelve nearly equal monthly installments beginning on April 18, 2022. F2 · balance_after: Includes 110,264 shares received pursuant to unvested restricted stock unit grants. Such shares vest to the extent of 1,037 shares beginning on April 18, 2022 and continuing monthly through September 18, 2022, 1,036 shares beginning on October 18, 2022 and continuing monthly through February 18, 2023, 49,949 shares on March 18, 2023 and 48,913 shares on March 18, 2024. Read SEC document |
| November 19, 2021 Filed Nov 22, 2021 17:17 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 4,000 | $6.66 | $26,626.00 |
DisclosureSEC source: 0001567619-21-020924 · doc1.xml · nonDerivative · entry 2 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 11,829 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.605 to $6.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 22:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 4,000 | $6.63 | $26,500.00 |
DisclosureSEC source: 0001567619-21-020585 · doc1.xml · nonDerivative · entry 3 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 7,829 Read SEC document |
| November 16, 2021 Filed Nov 16, 2021 22:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 3,826 | $6.83 | $26,131.58 |
DisclosureSEC source: 0001567619-21-020585 · doc1.xml · nonDerivative · entry 2 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 3,829 F2 · price: The price reported is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $6.73 to $6.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 22:35 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 42,059 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-21-019498 · doc1.xml · derivative · entry 18 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,059 Underlying: Common Stock · 42,059 shares Expires 2031-11-04 F8 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 21,030 shares on November 4, 2021 with the remaining 21,029 shares vesting quarterly in eight nearly equal installments beginning on November 4, 2022. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 22:35 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 293,479 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-21-019498 · doc1.xml · derivative · entry 17 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,479 Underlying: Common Stock · 293,479 shares Expires 2031-03-18 F7 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with an adjusted exercise price and vesting dates. F6 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 146,740 shares on March 18, 2021, 36,684 shares on November 4, 2021 and the remaining 110,055 shares in six nearly equal quarterly installments beginning December 18, 2021 and continuing every three months thereafter until fully vested. Read SEC document |
| November 04, 2021 Filed Nov 8, 2021 22:35 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 293,479 | $0.00 Strike: $47.60 | $0.00 |
DisclosureSEC source: 0001567619-21-019498 · doc1.xml · derivative · entry 16 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 293,794 shares Expires 2031-03-18 F2 · shares: Reflects a 1-for-4,000 reverse split effected by the issuer on October 27, 2021. F7 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with an adjusted exercise price and vesting dates. F5 · derivative.exercise_date: The option vests to the extent of 146,740 shares on March 18, 2021, 73,370 shares on March 18, 2022 and 73,369 shares on March 18, 2023. F2 · derivative.underlying_shares: Reflects a 1-for-4,000 reverse split effected by the issuer on October 27, 2021. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:05 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 1,173,917,974 | $0.00 Strike: $0.01 | $0.00 |
DisclosureSEC source: 0001567619-21-006692 · doc1.xml · derivative · entry 18 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,173,917,974 Underlying: Common Stock · 1,173,917,974 shares Expires 2031-03-18 F14 · derivative.exercise_date: Such shares vest to the extent of 586,958,987 shares on the date of grant, 293,479,494 shares on March 18, 2022 and 293,479,493 shares on March 18, 2023. Read SEC document |
| March 18, 2021 Filed Mar 19, 2021 21:05 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantCommon Stock | 586,958,987 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-21-006692 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595,390,616 F1 · price: Shares received pursuant to a restricted stock unit grant. Vests in three nearly equal annual installments beginning March 18, 2022. F2 · balance_after: Includes 586,958,987 shares received pursuant to an unvested restricted stock unit grant. Such shares vest to the extent of 195,652,996 shares on each of March 18, 2022 and March 18, 2023 and 195,652,995 shares on March 18, 2024. Read SEC document |
| November 23, 2020 Filed Nov 24, 2020 21:02 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | OtherCommon Stock | 8,375,671 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-20-020265 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · Director · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,431,629 F12 · kind: Shares acquired from Issuer pursuant to amended joint plan of reorganization of Issuer (the "Plan"). Pursuant to the Plan, 100 shares of common stock were issued for each dollar of allowed unsecured claim. F12 · price: Shares acquired from Issuer pursuant to amended joint plan of reorganization of Issuer (the "Plan"). Pursuant to the Plan, 100 shares of common stock were issued for each dollar of allowed unsecured claim. Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 21:04 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 18,455 | $0.24 | $4,429.20 |
DisclosureSEC source: 0001567619-19-018006 · doc1.xml · nonDerivative · entry 2 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,958 Read SEC document |
| September 04, 2019 Filed Sep 6, 2019 21:04 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,500 | $0.24 | $588.75 |
DisclosureSEC source: 0001567619-19-018006 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,503 Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 20:34 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 10,500 | $0.28 | $2,940.00 |
DisclosureSEC source: 0001567619-19-017786 · doc1.xml · nonDerivative · entry 3 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,003 Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 20:34 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 5,000 | $0.28 | $1,399.50 |
DisclosureSEC source: 0001567619-19-017786 · doc1.xml · nonDerivative · entry 2 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,503 Read SEC document |
| August 30, 2019 Filed Sep 3, 2019 20:34 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 2,500 | $0.26 | $650.00 |
DisclosureSEC source: 0001567619-19-017786 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,503 Read SEC document |
| August 26, 2019 Filed Aug 28, 2019 20:24 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 4,000 | $0.25 | $1,000.00 |
DisclosureSEC source: 0001567619-19-017635 · doc1.xml · nonDerivative · entry 2 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,003 Read SEC document |
| August 26, 2019 Filed Aug 28, 2019 20:24 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 3,500 | $0.29 | $1,015.00 |
DisclosureSEC source: 0001567619-19-017635 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 12,116 Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 20:42 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 8,928 | $0.28 | $2,499.84 |
DisclosureSEC source: 0001567619-19-017530 · doc1.xml · nonDerivative · entry 2 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,003 Read SEC document |
| August 22, 2019 Filed Aug 23, 2019 20:42 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | PurchaseCommon Stock | 8,446 | $0.23 | $1,945.96 |
DisclosureSEC source: 0001567619-19-017530 · doc1.xml · nonDerivative · entry 1 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Indirect · IRA Disclosed balance after: 8,616 Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 100,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 32 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-10-29 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F11 · derivative.exercise_date: The option is exercisable to the extent of 33,334 shares on October 29, 2019, and 33,333 shares on each of October 29, 2020 and October 29, 2021. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 100,000 | Not disclosed Strike: $1.23 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 31 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100,000 shares Expires 2028-10-29 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F11 · derivative.exercise_date: The option is exercisable to the extent of 33,334 shares on October 29, 2019, and 33,333 shares on each of October 29, 2020 and October 29, 2021. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 80,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 30 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2027-07-12 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F10 · derivative.exercise_date: The option is exercisable to the extent of 26,667 shares on each of July 12, 2018 and July 12, 2019, and 26,666 shares on July 12, 2020. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 80,000 | Not disclosed Strike: $2.80 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 29 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 80,000 shares Expires 2027-07-12 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F10 · derivative.exercise_date: The option is exercisable to the extent of 26,667 shares on each of July 12, 2018 and July 12, 2019, and 26,666 shares on July 12, 2020. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 21:26 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 60,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007667 · doc1.xml · derivative · entry 28 Silva Francisco · CIK 0001527241 · VP of Research and Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2026-06-10 F12 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F9 · derivative.exercise_date: The option is exercisable to the extent of 20,000 shares on each of June 10, 2017, June 10, 2018 and June 10, 2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.